Biopharma Money on the Move: October 21-27
The Pharma Data
OCTOBER 27, 2020
Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer. Primmune’s early data shows the potential for PRTX007 to drive the natural innate immune response to combat systemic diseases. .
Let's personalize your content